Charles River Laboratories International (CRL) Expected to Release Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $2.72 per share and revenue of $976.0980 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company earned $2.34 EPS. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $240.78 on Wednesday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The company has a 50 day moving average price of $202.05 and a 200-day moving average price of $187.59. Charles River Laboratories International has a 1-year low of $144.26 and a 1-year high of $242.73. The firm has a market cap of $11.60 billion, a price-to-earnings ratio of -64.04, a price-to-earnings-growth ratio of 2.50 and a beta of 1.40.

Analysts Set New Price Targets

CRL has been the topic of several analyst reports. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price target on the stock. Evercore reiterated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research note on Monday, July 20th. Morgan Stanley raised their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Finally, Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average price target of $220.75.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in CRL. Mercer Global Advisors Inc. ADV raised its stake in Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after purchasing an additional 80 shares during the last quarter. Advisory Services Network LLC boosted its stake in Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Charles River Laboratories International by 14.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the medical research company’s stock worth $150,000 after purchasing an additional 94 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Charles River Laboratories International by 0.6% during the third quarter. Public Employees Retirement System of Ohio now owns 15,240 shares of the medical research company’s stock worth $2,384,000 after buying an additional 95 shares in the last quarter. Finally, Brown Advisory Inc. raised its position in shares of Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after buying an additional 114 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.